Skip to main content

Advertisement

SpringerLink
Log in

The economics of stone disease

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

The rising prevalence of kidney stone disease is associated with significant costs to healthcare systems worldwide. This is in part due to direct procedural and medical management costs, as well as indirect costs to health systems, patients, and families. A number of manuscripts evaulating the economics of stone disease have been published since the 2008s International Consultation on Stone Disease. These highlight costs associated with stone disease, including acute management, surgical management, and medical management. This work hopes to highlight optimization in care by reducing inefficient treatments and maximizing cost-efficient preventative strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pearle MS, Calhoun EA, Curhan GC, Urologic Diseases of America Project (2005) Urologic diseases in America project: urolithiasis. J Urol 173(3):848–857

    Article  PubMed  Google Scholar 

  2. Saigal CS, Joyce G, Timilsina AR, Urologic Diseases in America Project (2005) Direct and indirect costs of nephrolithiasis in an employed population: opportunity for disease management? Kidney Int 68(4):1808–1814

    Article  PubMed  Google Scholar 

  3. Bensalah K, Pearle M, Lotan Y (2008) Cost-effectiveness of medical expulsive therapy using alpha-blockers for the treatment of distal ureteral stones. Eur Urol 53(2):411–418

    Article  PubMed  Google Scholar 

  4. Izamin I, Aniza I, Rizal AM, Aljunid SM (2009) Comparing extracorporeal shock wave lithotripsy and ureteroscopy for treatment of proximal ureteric calculi: a cost-effectiveness study. Med J Malays 64(1):12–21

    CAS  Google Scholar 

  5. Bagrodia A, Gupta A, Raman JD, Bensalah K, Pearle MS, Lotan Y (2009) Predictors of cost and clinical outcomes of percutaneous nephrostolithotomy. J Urol 182(2):586–590

    Article  PubMed  Google Scholar 

  6. Bagrodia A, Raman JD, Bensalah K, Pearle MS, Lotan Y (2009) Synchronous bilateral percutaneous nephrostolithotomy: analysis of clinical outcomes, cost and surgeon reimbursement. J Urol 181(1):149–153

    Article  PubMed  Google Scholar 

  7. Koo V, Beattie I, Young M (2010) Improved cost-effectiveness and efficiency with a slower shockwave delivery rate. BJU Int 105(5):692–696

    Article  PubMed  Google Scholar 

  8. Raman JD, Bagrodia A, Bensalah K, Pearle MS, Lotan Y (2010) Residual fragments after percutaneous nephrolithotomy: cost comparison of immediate second look flexible nephroscopy versus expectant management. J Urol 183(1):188–193

    Article  PubMed  Google Scholar 

  9. Chu L, Farris CA, Corcoran AT, Averch TD (2011) Preoperative stent placement decreases cost of ureteroscopy. Urology 78(2):309–313

    Article  PubMed  Google Scholar 

  10. Koo V, Young M, Thompson T, Duggan B (2011) Cost-effectiveness and efficiency of shockwave lithotripsy vs flexible ureteroscopic holmium:yttrium-aluminium-garnet laser lithotripsy in the treatment of lower pole renal calculi. BJU Int 108(11):1913–1916

    Article  PubMed  Google Scholar 

  11. Lotan Y, Buendia Jiménez I, Lenoir-Wijnkoop I, Daudon M, Molinier L, Tack I, Nuijten MJC (2012) Primary prevention of nephrolithiasis is cost-effective for a national healthcare system. BJU Int 110(11 Pt C):E1060–E1067.

    Google Scholar 

  12. Hollingsworth JM, Saigal CS, Lai JC, Dunn RL, Strope SA, Hollenbeck BK, Urologic Diseases in America Project (2012) Medicare payments for outpatient urological surgery by location of care. J Urol 188(6):2323–2327

    Article  PubMed  PubMed Central  Google Scholar 

  13. Eaton SH, Cashy J, Pearl JA, Stein DM, Perry K, Nadler RB (2013) Admission rates and costs associated with emergency presentation of urolithiasis: analysis of the Nationwide Emergency Department Sample 2006–2009. J Endourol 27(12):1535–1538

    Article  PubMed  PubMed Central  Google Scholar 

  14. Gurbuz C, Atis G, Arikan O, Efilioglu O, Yildirim A, Danacioglu O, Caskurlu T (2014) The cost analysis of flexible ureteroscopic lithotripsy in 302 cases. Urolithiasis 42(2):155–158

    Article  PubMed  Google Scholar 

  15. Hollingsworth JM, Norton EC, Kaufman SR, Smith RM, Wolf JSJ, Hollenbeck BK (2013) Medical expulsive therapy versus early endoscopic stone removal for acute renal colic: an instrumental variable analysis. J Urol 190(3):882–887

    Article  PubMed  Google Scholar 

  16. Pan J, Chen Q, Xue W, Chen Y, Xia L, Chen H, Huang Y (2013) RIRS versus mPCNL for single renal stone of 2–3 cm: clinical outcome and cost-effective analysis in Chinese medical setting. Urolithiasis 41(1):73–78

    Article  PubMed  Google Scholar 

  17. Sutherland TN, Pearle MS, Lotan Y (2013) How much is a kidney worth? Cost-effectiveness of routine imaging after ureteroscopy to prevent silent obstruction. J Urol 189(6):2136–2141

    Article  PubMed  Google Scholar 

  18. Ursiny M, Eisner BH (2013) Cost-effectiveness of anti-retropulsion devices for ureteroscopic lithotripsy. J Urol 189(5):1762–1766

    Article  PubMed  Google Scholar 

  19. Health at a Glance 2015. OECD Indicators (2015). Accessed Oct 17, 2016. http://www.oecd.org/health/health-at-a-glance-19991312.htm

  20. Chandhoke PS (2002) When is medical prophylaxis cost-effective for recurrent calcium stones? J Urol 168(3):937–940

    Article  PubMed  Google Scholar 

  21. Strohmaier WL (2000) Socioeconomic aspects of urinary calculi and metaphylaxis of urinary calculi. Der Urologe Ausg A 39(2):166–170

    Article  CAS  PubMed  Google Scholar 

  22. Resnick MI, Persky L (1995) Summary of the National Institutes of Arthritis, Diabetes, Digestive and Kidney Diseases conference on urolithiasis: state of the art and future research needs. J Urol 153(1):4–9

    Article  CAS  PubMed  Google Scholar 

  23. Ahlstrand C, Tiselius HG (1981) Renal stone disease in a Swedish district during one year. Scand J Urol Nephrol 15(2):143–146

    Article  CAS  PubMed  Google Scholar 

  24. Hollingsworth JM, Rogers MAM, Kaufman SR, Bradford TJ, Saint S, Wei JT, Hollenbeck BK (2006) Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet. 368(9542):1171–1179.

    Article  PubMed  Google Scholar 

  25. Porpiglia F, Destefanis P, Fiori C, Fontana D (2000) Effectiveness of nifedipine and deflazacort in the management of distal ureter stones. Urology 56(4):579–582

    Article  CAS  PubMed  Google Scholar 

  26. Borghi L, Meschi T, Amato F, Novarini A, Giannini A, Quarantelli C, Mineo F (1994) Nifedipine and methylprednisolone in facilitating ureteral stone passage: a randomized, double-blind, placebo-controlled study. J Urol 152(4):1095–1098

    Article  CAS  PubMed  Google Scholar 

  27. Yilmaz E, Batislam E, Basar MM, Tuglu D, Ferhat M, Basar H (2005) The comparison and efficacy of 3 different alpha1-adrenergic blockers for distal ureteral stones. J Urol 173(6):2010–2012

    Article  CAS  PubMed  Google Scholar 

  28. Dauw CA, Kaufman SR, Hollenbeck BK, Roberts WW, Faerber GJ, Wolf JS, Hollingsworth JM (2014) Expulsive therapy versus early endoscopic stone removal in patients with acute renal colic: a comparison of indirect costs. J Urol 191(3):673–677

    Article  PubMed  Google Scholar 

  29. Hollingsworth JM, Davis MM, West BT, Wolf JSJ, Hollenbeck BK (2009) Trends in medical expulsive therapy use for urinary stone disease in U.S. emergency departments. Urology 74(6):1206–1209

    Article  PubMed  Google Scholar 

  30. Morris DS, Wei JT, Taub DA, Dunn RL, Wolf JSJ, Hollenbeck BK (2006) Temporal trends in the use of percutaneous nephrolithotomy. J Urol 175(5):1731–1736

    Article  PubMed  Google Scholar 

  31. Seklehner S, Laudano MA, Jamzadeh A, Del Pizzo JJ, Chughtai B, Lee RK (2014) Trends and inequalities in the surgical management of ureteric calculi in the USA. BJU Int 113(3):476–483

    Article  PubMed  Google Scholar 

  32. Hollingsworth JM, Krein SL, Birkmeyer JD, Ye Z, Kim HM, Zhang Y, Hollenbeck BK (2010) Opening ambulatory surgery centers and stone surgery rates in health care markets. J Urol 184(3):967–971

    Article  PubMed  Google Scholar 

  33. Hyams ES, Shah O (2009) Percutaneous nephrostolithotomy versus flexible ureteroscopy/holmium laser lithotripsy: cost and outcome analysis. J Urol 182(3):1012–1017

    Article  PubMed  Google Scholar 

  34. Feng MI, Tamaddon K, Mikhail A, Kaptein JS, Bellman GC (2001) Prospective randomized study of various techniques of percutaneous nephrolithotomy. Urology 58(3):345–350

    Article  CAS  PubMed  Google Scholar 

  35. Grasso M, Beaghler M, Loisides P (1995) The case for primary endoscopic management of upper urinary tract calculi: II. Cost and outcome assessment of 112 primary ureteral calculi. Urology 45(3):372–376

    Article  CAS  PubMed  Google Scholar 

  36. Kapoor DA, Leech JE, Yap WT, Rose JF, Kabler R, Mowad JJ (1992) Cost and efficacy of extracorporeal shock wave lithotripsy versus ureteroscopy in the treatment of lower ureteral calculi. J Urol 148(3 Pt 2):1095–1096

    Article  CAS  PubMed  Google Scholar 

  37. Anderson KR, Keetch DW, Albala DM, Chandhoke PS, McClennan BL, Clayman RV (1994) Optimal therapy for the distal ureteral stone: extracorporeal shock wave lithotripsy versus ureteroscopy. J Urol 152(1):62–65

    Article  CAS  PubMed  Google Scholar 

  38. Parker BD, Frederick RW, Reilly TP, Lowry PS, Bird ET (2004) Efficiency and cost of treating proximal ureteral stones: shock wave lithotripsy versus ureteroscopy plus holmium:yttrium-aluminum-garnet laser. Urology 64(6):1102–1106

    Article  PubMed  Google Scholar 

  39. Wu CF, Chen CS, Lin WY, Shee JJ, Lin CL, Chen Y, Huang WS (2005) Therapeutic options for proximal ureter stone: extracorporeal shock wave lithotripsy versus semirigid ureterorenoscope with holmium:yttrium-aluminum-garnet laser lithotripsy. Urology 65(6):1075–1079

    Article  PubMed  Google Scholar 

  40. Lotan Y, Gettman MT, Roehrborn CG, Cadeddu JA, Pearle MS (2002) Management of ureteral calculi: a cost comparison and decision making analysis. J Urol 167(4):1621–1629

    Article  PubMed  Google Scholar 

  41. Pearle MS, Roehrborn CG, Pak CY (1999) Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. J Endourol 13(9):679–685

    Article  CAS  PubMed  Google Scholar 

  42. Lotan Y, Cadeddu JA, Pearle MS (2005) International comparison of cost effectiveness of medical management strategies for nephrolithiasis. Urol Res 33(3):223–230

    Article  PubMed  Google Scholar 

  43. Lotan Y, Cadeddu JA, Roerhborn CG, Pak CY, Pearle MS (2004) Cost-effectiveness of medical management strategies for nephrolithiasis. J Urol 172(6 Pt 1):2275–2281

    Article  PubMed  Google Scholar 

  44. Lotan Y, Pearle MS (2011) Cost-effectiveness of primary prevention strategies for nephrolithiasis. J Urol 186(2):550–555

    Article  PubMed  Google Scholar 

  45. Lotan Y, Buendia Jimenez I, Lenoir-Wijnkoop I, Daudon M, Molinier L, Tack I, Nuijten MJ (2013) Increased water intake as a prevention strategy for recurrent urolithiasis: major impact of compliance on cost-effectiveness. J Urol 189(3):935–939

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9110, USA

    Noah E. Canvasser & Yair Lotan

  2. Department of Urology, Mannheim University Hospital, Mannheim, Germany

    Peter Alken

  3. Department of Urology, Duke University, Durham, NC, USA

    Michael Lipkin

  4. Department of Urology, University of Wisconsin, Madison, WI, USA

    Stephen Y. Nakada

  5. Department of Urology, RG Stone Urology and Laparoscopy Hospital, Andheri, Mumbai, India

    Hiren S. Sodha

  6. Department of Urology, Sen Jorj Austria Hospital, Beyoglu, Istanbul, Turkey

    Abdulkadir Tepeler

Authors
  1. Noah E. Canvasser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Alken
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Lipkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stephen Y. Nakada
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiren S. Sodha
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Abdulkadir Tepeler
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yair Lotan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yair Lotan.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Funding

None.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Canvasser, N.E., Alken, P., Lipkin, M. et al. The economics of stone disease. World J Urol 35, 1321–1329 (2017). https://doi.org/10.1007/s00345-017-2003-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-017-2003-y

Keywords

Search

Navigation